IBDEI2F9 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40669,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,40670,0)
 ;;=E11.622^^189^2084^34
 ;;^UTILITY(U,$J,358.3,40670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40670,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,40670,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,40670,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,40671,0)
 ;;=E11.628^^189^2084^33
 ;;^UTILITY(U,$J,358.3,40671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40671,1,3,0)
 ;;=3^DM Type 2 w/ Skin Compl NEC
 ;;^UTILITY(U,$J,358.3,40671,1,4,0)
 ;;=4^E11.628
 ;;^UTILITY(U,$J,358.3,40671,2)
 ;;=^5002658
 ;;^UTILITY(U,$J,358.3,40672,0)
 ;;=E11.69^^189^2084^19
 ;;^UTILITY(U,$J,358.3,40672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40672,1,3,0)
 ;;=3^DM Type 2 w/ Complications NEC
 ;;^UTILITY(U,$J,358.3,40672,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,40672,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,40673,0)
 ;;=E11.8^^189^2084^20
 ;;^UTILITY(U,$J,358.3,40673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40673,1,3,0)
 ;;=3^DM Type 2 w/ Complications,Unspec
 ;;^UTILITY(U,$J,358.3,40673,1,4,0)
 ;;=4^E11.8
 ;;^UTILITY(U,$J,358.3,40673,2)
 ;;=^5002665
 ;;^UTILITY(U,$J,358.3,40674,0)
 ;;=E10.51^^189^2084^13
 ;;^UTILITY(U,$J,358.3,40674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40674,1,3,0)
 ;;=3^DM Type 1 w/ Diab Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,40674,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,40674,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,40675,0)
 ;;=E10.52^^189^2084^12
 ;;^UTILITY(U,$J,358.3,40675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40675,1,3,0)
 ;;=3^DM Type 1 w/ Diab Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,40675,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,40675,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,40676,0)
 ;;=E10.59^^189^2084^1
 ;;^UTILITY(U,$J,358.3,40676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40676,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Compl NEC
 ;;^UTILITY(U,$J,358.3,40676,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,40676,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,40677,0)
 ;;=E10.610^^189^2084^10
 ;;^UTILITY(U,$J,358.3,40677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40677,1,3,0)
 ;;=3^DM Type 1 w/ Diab Neuropathy Arthropathy
 ;;^UTILITY(U,$J,358.3,40677,1,4,0)
 ;;=4^E10.610
 ;;^UTILITY(U,$J,358.3,40677,2)
 ;;=^5002613
 ;;^UTILITY(U,$J,358.3,40678,0)
 ;;=E10.618^^189^2084^5
 ;;^UTILITY(U,$J,358.3,40678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40678,1,3,0)
 ;;=3^DM Type 1 w/ Diab Arthopathy NEC
 ;;^UTILITY(U,$J,358.3,40678,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,40678,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,40679,0)
 ;;=E10.620^^189^2084^7
 ;;^UTILITY(U,$J,358.3,40679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40679,1,3,0)
 ;;=3^DM Type 1 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,40679,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,40679,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,40680,0)
 ;;=E10.621^^189^2084^15
 ;;^UTILITY(U,$J,358.3,40680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40680,1,3,0)
 ;;=3^DM Type 1 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,40680,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,40680,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,40681,0)
 ;;=E10.622^^189^2084^17
 ;;^UTILITY(U,$J,358.3,40681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40681,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,40681,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,40681,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,40682,0)
 ;;=E10.628^^189^2084^16
 ;;^UTILITY(U,$J,358.3,40682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40682,1,3,0)
 ;;=3^DM Type 1 w/ Skin Compl NEC
